Editas Medicine (EDIT) Stock Price, News & Analysis

Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.62 to $2.77
• 50-Day Range: $1.97 to $3.46
• 52-Week Range: $0.91 to $4.15
• Volume: 926,332 shs
• Average Volume: 2.24 million shs
• Market Capitalization: $240.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.10
• Consensus Rating: Hold

Editas Medicine Stock Analysis - MarketRank™

Editas Medicine scored higher than 84% of companies evaluated by MarketBeat, and ranked 168th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Editas Medicine has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Editas Medicine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Editas Medicine are expected to grow in the coming year, from ($2.71) to ($1.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Editas Medicine is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Editas Medicine is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Editas Medicine has a P/B Ratio of 12.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.58% of the float of Editas Medicine has been sold short.

Short Interest Ratio / Days to Cover

Editas Medicine has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Editas Medicine has recently decreased by 7.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Editas Medicine does not currently pay a dividend.

Dividend Growth

Editas Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.15

Percentage of Shares Shorted

9.58% of the float of Editas Medicine has been sold short.

Short Interest Ratio / Days to Cover

Editas Medicine has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Editas Medicine has recently decreased by 7.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.02

News Sentiment

Editas Medicine has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Editas Medicine this week, compared to 4 articles on an average week.

Search Interest

23 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 92% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,649.00 in company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Editas Medicine is held by insiders.

Percentage Held by Institutions

71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EDIT Stock Analysis - Frequently Asked Questions

How have EDIT shares performed this year?

Editas Medicine's stock was trading at $1.27 at the start of the year. Since then, EDIT shares have increased by 110.2% and is now trading at $2.67.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.22. The company earned $3.58 million during the quarter, compared to the consensus estimate of $1.81 million. Editas Medicine had a negative trailing twelve-month return on equity of 200.25% and a negative net margin of 608.88%.

When did Editas Medicine IPO?

Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Top institutional shareholders of Editas Medicine include Geode Capital Management LLC (2.35%), Bank of America Corp DE (1.20%), JPMorgan Chase & Co. (1.27%) and Kennedy Capital Management LLC (0.68%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Michelle Robertson, Bruce Eaton, Jessica Hopfield, Mark S Shearman, Linda Burkly and Amy Parison.
View institutional ownership trends.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/20/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EDIT
• CIK: 1650664
• Web: www.editasmedicine.com
• Phone: (617) 401-9000
• Fax: N/A
• Employees: 230
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Editas Medicine: $5.10
• High Price Target: $12.00
• Low Price Target: $1.00
• Potential Upside/Downside: +91.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.23
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$237.09 million
• Net Margins: -608.88%
• Pretax Margin: -608.88%
• Return on Equity: -200.25%
• Return on Assets: -68.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $32.31 million
• Price / Sales: 7.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 12.71

Miscellaneous

• Outstanding Shares: 89,920,000
• Free Float: 88,032,000
• Market Cap: $240.09 million
• Optionable: Optionable
• Beta: 2.19